{"id":"aripiprazole-6-week-group","safety":{"commonSideEffects":[{"rate":"10-25%","effect":"Akathisia"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-15%","effect":"Anxiety"},{"rate":"5-15%","effect":"Insomnia"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Weight gain"},{"rate":"5-10%","effect":"Tremor"},{"rate":"5-10%","effect":"Sedation"}]},"_chembl":{"chemblId":"CHEMBL2219425","moleculeType":"Small molecule","molecularWeight":"660.73"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aripiprazole acts as a partial agonist at dopamine D2 and D3 receptors, providing dopaminergic stabilization rather than pure antagonism. This mechanism reduces excessive dopaminergic activity in hyperactive pathways while supporting activity in hypoactive pathways. It also has serotonin 5-HT1A partial agonist and 5-HT2A antagonist properties, contributing to its antipsychotic and mood-stabilizing effects.","oneSentence":"Aripiprazole is a dopamine D2/D3 receptor partial agonist that modulates dopaminergic and serotonergic neurotransmission to treat psychiatric disorders.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:27:36.925Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar I disorder (acute manic or mixed episodes)"},{"name":"Major depressive disorder (adjunctive treatment)"},{"name":"Irritability associated with autism spectrum disorder"}]},"trialDetails":[{"nctId":"NCT03442101","phase":"","title":"Trajectories of Treatment Response as Window Into the Heterogeneity of Psychosis: a Longitudinal Multimodal Imaging Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2018-04-01","conditions":"Psychosis","enrollment":156},{"nctId":"NCT06433635","phase":"PHASE4","title":"Sequential Multiple Assignment Randomized Trial for Bipolar Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-10-01","conditions":"Bipolar I Disorder, Depression","enrollment":2726},{"nctId":"NCT06236451","phase":"PHASE4","title":"Atypical Antipsychotic-induced Mitochondrial Dysfunction in Patients With Schizophrenia","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2024-04-05","conditions":"Schizophrenia","enrollment":60},{"nctId":"NCT06467474","phase":"NA","title":"Psychoeducational Group for Depression","status":"RECRUITING","sponsor":"Ricardo Alberto Moreno, M.D., Ph.D.","startDate":"2024-03-01","conditions":"Major Depressive Disorder (MDD","enrollment":338},{"nctId":"NCT04203056","phase":"PHASE4","title":"Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode","status":"TERMINATED","sponsor":"University of California, Los Angeles","startDate":"2019-12-16","conditions":"Schizophrenia, Schizoaffective Disorder, Depressive Type, Schizophreniform Disorder","enrollment":15},{"nctId":"NCT05889234","phase":"","title":"Multimodal Magnetic Resonance Imaging-based Study of Electroconvulsive Efficacy Prediction in Adolescents With Depression: a Multicenter Prospective Cohort Study","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2023-11-06","conditions":"Major Depressive Disorder, Magnetic Resonance Imaging, Electroconvulsive Therapy","enrollment":180},{"nctId":"NCT05868720","phase":"NA","title":"EFFECT OF RISPERIDONE vs ARIPIPRAZOLE ON OXIDATIVE STRESS IN PATIENTS WITH AUTISM SPECTRUM DISORDER: A RANDOMIZED CONTROLLED TRIAL","status":"UNKNOWN","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2023-07-01","conditions":"The Goal of This Trial is to to Compare the Effect of Risperidone vs Aripiprazole in Terms of Change in Serum Glutathione Level","enrollment":42},{"nctId":"NCT01123707","phase":"PHASE3","title":"To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-11-18","conditions":"Major Depressive Disorder (MDD)","enrollment":173},{"nctId":"NCT01111565","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-10-04","conditions":"Major Depressive Disorder (MDD)","enrollment":137},{"nctId":"NCT01111552","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-07-29","conditions":"Major Depressive Disorder (MDD)","enrollment":237},{"nctId":"NCT03451734","phase":"","title":"Optimizing and Individualizing the Pharmacological Treatment of First-episode Schizophrenic Patients","status":"COMPLETED","sponsor":"Central South University","startDate":"2018-01-23","conditions":"Schizophrenia, Metabolic Syndrome","enrollment":2000},{"nctId":"NCT04765085","phase":"NA","title":"Clinical Efficacy and Change of Life Quality Through Using the Comprehensive Behavioral Intervention Treatment for Tics","status":"WITHDRAWN","sponsor":"Children's Hospital of Fudan University","startDate":"2021-03","conditions":"Tic Disorders","enrollment":""},{"nctId":"NCT03881449","phase":"PHASE4","title":"DIMES - DIgital MEdicine Study for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole","status":"UNKNOWN","sponsor":"Durham VA Medical Center","startDate":"2019-04-04","conditions":"Schizophrenia, Major Depressive Disorder, Bi-Polar Disorder","enrollment":46},{"nctId":"NCT01696617","phase":"PHASE4","title":"Aripiprazole (Abilify®) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2012-02-10","conditions":"Major Depressive Disorder","enrollment":46},{"nctId":"NCT03358277","phase":"NA","title":"Aripiprazole Added on for DMDD in Youths With ADHD","status":"COMPLETED","sponsor":"Tri-Service General Hospital","startDate":"2014-11-19","conditions":"Disruptive Mood Dysregulation Disorder","enrollment":58},{"nctId":"NCT01942161","phase":"PHASE2, PHASE3","title":"A Short Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2010-08","conditions":"Schizophrenia","enrollment":106},{"nctId":"NCT00876343","phase":"PHASE3","title":"Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2009-03","conditions":"Major Depressive Disorder","enrollment":586},{"nctId":"NCT01009047","phase":"PHASE3","title":"An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2009-12","conditions":"Schizophrenia","enrollment":228}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Abilify®"],"phase":"marketed","status":"active","brandName":"Aripiprazole 6-week group","genericName":"Aripiprazole 6-week group","companyName":"Seoul National University Hospital","companyId":"seoul-national-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aripiprazole is a dopamine D2/D3 receptor partial agonist that modulates dopaminergic and serotonergic neurotransmission to treat psychiatric disorders. Used for Schizophrenia, Bipolar I disorder (acute manic or mixed episodes), Major depressive disorder (adjunctive treatment).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}